Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 31, 2026

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker
07:47

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Published on: September 15, 2023

Pan-Cancer Analysis Identifies GNPNAT1 as a Potential Prognostic Biomarker and Immune-Related Factor.

Yujie Liu1, Tusheng Wu1, Yuan Wang1

  • 1Department of Gynecological Radiotherapy, Harbin Medical University Cancer Hospital, 150081 Harbin, Heilongjiang, China.

Frontiers in Bioscience (Landmark Edition)
|May 30, 2026
PubMed
Summary

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Suppressing reverse intersystem crossing <i>via</i> ring-fusion: turning fluorophores into efficient photosensitizers.

Chemical communications (Cambridge, England)·2026
Same author

MARVELD1 regulates hepatocyte transformation via maintaining NF-κB signaling homeostasis mediated by the CCL5/CCR5 axis between hepatic stellate cells and hepatocytes.

Cell communication and signaling : CCS·2026
Same author

ePRO-Guided Symptom Management In Breast Cancer Adjuvant Radiotherapy: A Prospective Controlled Study.

Journal of visualized experiments : JoVE·2026
Same author

Red-to-Blue Photon Upconversion Based on BODIPY Derivative Photosensitizers.

Chemistry (Weinheim an der Bergstrasse, Germany)·2026
Same author

Macrophage exosome-modified Mn/Se nanoheterostructure induces post-infarction cardiomyocyte regeneration and immunometabolic microenvironment repair.

Journal of nanobiotechnology·2026
Same author

The Evolution of Precision Anti-Doping From UGT2B17 Polymorphism Insights to Integrated Detection Frameworks.

Drug testing and analysis·2026

Glucosamine 6-phosphate N-acetyltransferase 1 (GNPNAT1) is a key enzyme in the hexosamine biosynthetic pathway (HBP). This study reveals GNPNAT1

Area of Science:

  • Biochemistry
  • Cancer Biology
  • Immunology

Background:

  • Glucosamine 6-phosphate N-acetyltransferase 1 (GNPNAT1) is a rate-limiting enzyme in the hexosamine biosynthetic pathway (HBP).
  • The expression patterns, clinical relevance in cancers, and impact on the tumor immune microenvironment of GNPNAT1 are not well understood.

Purpose of the Study:

  • To investigate the differential expression of GNPNAT1 across various cancer types.
  • To explore the association of GNPNAT1 expression with patient prognosis, tumor stemness, mutational profiles, RNA modifications, immune microenvironment, and drug sensitivity.
  • To elucidate the functional role and signaling pathways of GNPNAT1 in cervical cancer (CC).

Main Methods:

  • Pan-cancer analysis of GNPNAT1 expression using multi-omics data from multiple databases.
Keywords:
GNPNAT1biological markersimmunityneoplasmsprognosis

Related Experiment Videos

Last Updated: May 31, 2026

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker
07:47

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Published on: September 15, 2023

  • Correlation analyses between GNPNAT1 expression and clinical/molecular features.
  • In vitro functional experiments (GNPNAT1 knockdown) and enrichment analyses in cervical cancer.

    • Main Results:

    • GNPNAT1 shows aberrant expression in multiple tumor types, significantly impacting patient prognosis.
    • GNPNAT1 expression correlates with tumor mutational profiles, RNA modifications, drug sensitivity, and immune factors (checkpoint genes, chemokines).
    • GNPNAT1 knockdown in CC cells reduced proliferation and migration, suggesting involvement in cell adhesion and immune pathways.

    Conclusions:

    • GNPNAT1 is a potential prognostic biomarker, particularly for cervical cancer.
    • GNPNAT1's role in immune regulation and treatment resistance suggests its potential as a target for novel immunotherapy strategies.